
24
5.2 Potential Adverse Events
Adverse events that may occur and/or require intervention include, but are
not limited to:
• Amputation
• Anesthetic complications and subsequent attendant problems (e.g.,
aspiration)
• Aneurysm enlargement
• Aneurysm rupture and death
• Aortic damage, including perforation, dissection, bleeding, rupture and
death
• Arterial or venous thrombosis and/or pseudoaneurysm
• Arteriovenous fistula
• Bleeding, hematoma or coagulopathy
• Bowel complications (e.g., ileus, transient ischemia, infarction, necrosis)
• Cardiac complications and subsequent attendant problems (e.g.,
arrhythmia, myocardial infarction, congestive heart failure, hypotension,
hypertension)
• Claudication (e.g., buttock, lower limb)
• Death
• Edema
• Embolization (micro and macro) with transient or permanent ischemia or
infarction
• Endoleak
• Endoprosthesis: improper component placement; incomplete component
deployment; component migration; suture break; occlusion; infection;
stent fracture; graft material wear; dilatation; erosion; puncture; perigraft
flow; barb separation and corrosion
• Fever and localized inflammation
• Genitourinary complications and subsequent attendant problems (e.g.,
ischemia, erosion, fistula, incontinence, hematuria, infection)
• Graft or native vessel occlusion
• Hepatic failure
• Impotence
• Infection of the aneurysm, device or access site, including abscess
formation, transient fever and pain
• Lymphatic complications and subsequent attendant problems (e.g., lymph
fistula)
• Neurologic local or systemic complications and subsequent attendant
problems (e.g., stroke, transient ischemic attack, paraplegia, paraparesis,
paralysis)
• Pulmonary/respiratory complications and subsequent attendant problems
(e.g., pneumonia, respiratory failure, prolonged intubation)
• Renal complications and subsequent attendant problems (e.g., artery
occlusion, contrast toxicity, insufficiency, failure)
• Surgical conversion to open repair
• Vascular access site complications, including infection, pain, hematoma,
pseudoaneurysm, arteriovenous fistula
• Vessel damage
• Wound complications and subsequent attendant problems (e.g.,
dehiscence, infection)
• Vascular spasm or vascular trauma (e.g., iliofemoral vessel dissection,
bleeding, rupture, death)
Device-Related Adverse Event Reporting
Any adverse event (clinical incident) involving the Zenith Flex AAA
Endovascular Graft should be reported to COOK immediately. For customers
in the United States, to report an incident, call the Customer Relations
Department at 1-800-457-4500 (24 hour) or 1-812-339-2235. For customers
outside the United States, please call your distributor.
Table 5.1.2 Adverse Events
1
in Clinical Study
Zenith Standard Risk
Surgical Standard Risk
P
value
Zenith High Risk
Zenith Roll-in
Freedom from Morbidity
80%
(160/200)
58%
(46/80)
<.001
68%
(68/100)
73%
(38/52)
(0-30 days)
Cardiovascular
2
3.0%
(6/200)
11%
(9/80)
.02
14%
(14/100)
1.9%
(1/52)
Pulmonary
3
1.0%
(2/200)
15%
(12/80)
<.001
2.0%
(2/100)
0.0%
(0/52)
Renal
4, 9
2.5%
(5/200)
10%
(8/80)
.01
6.0%
(6/100)
5.8%
(3/52)
Bowel
5
1.0%
(2/200)
3.8%
(3/80)
.14
1.0%
(1/100)
1.9%
(1/52)
Wound
6
4.5%
(9/200)
7.5%
(6/80)
.38
2.0%
(2/100)
3.8%
(2/52)
Neurologic
7
0.0%
(0/200)
2.5%
(2/80)
.08
0.0%
(0/100)
0.0%
(0/52)
Vascular
8,11
11%
(21/200)
31%
(25/80)
<.001
20%
(20/100)
19%
(10/52)
Freedom from Morbidity
91%
(181/198)
86%
(67/78)
.25
79%
(77/98)
86%
(44/51)
(31-365 days)
Cardiovascular
2
2.5%
(5/198)
3.8%
(3/78)
.69
5.1%
(5/98)
2.0%
(1/51)
Pulmonary
3
0.5%
(1/198)
1.3%
(1/78)
.49
4.1%
(4/98)
0.0%
(0/51)
Renal
4,10
0.5%
(1/198)
0.0%
(0/78)
>.99
3.1%
(3/98)
0.0%
(0/51)
Bowel
5
0.5%
(1/198)
1.3%
(1/78)
.49
0.0%
(0/98)
0.0%
(0/51)
Wound
6
2.0%
(4/198)
5.1%
(4/78)
.23
3.1%
(3/98)
2.0%
(1/51)
Neurologic
7
1.0%
(2/198)
0.0%
(0/78)
>.99
1.0%
(1/98)
3.9%
(2/51)
Vascular
8
3.0%
(6/198)
3.8%
(3/78)
.72
8.2%
(8/98)
5.9%
(3/51)
Freedom from Morbidity
76%
(151/200)
49%
(39/80)
<.001
55%
(55/100)
62%
(32/52)
(0-365 days)
Cardiovascular
2
5.0%
(10/200)
14%
(11/80)
.02
19%
(19/100)
3.8%
(2/52)
Pulmonary
3
1.5%
(3/200)
16%
(13/80)
<.001
6.0%
(6/100)
0.0%
(0/52)
Renal
4,9,10
2.5%
(5/200)
10%
(8/80)
.01
9.0%
(9/100)
5.8%
(3/52)
Bowel
5
1.5%
(3/200)
3.8%
(3/80)
.36
1.0%
(1/100)
1.9%
(1/52)
Wound
6
5.5%
(11/200)
13%
(10/80)
.08
5.0%
(5/100)
5.8%
(3/52)
Neurologic
7
1.0%
(2/200)
2.5%
(2/80)
.32
1.0%
(1/100)
3.8%
(2/52)
Vascular
8,11
12%
(24/200)
33%
(26/80)
<.001
25%
(25/100)
23%
(12/52)
1
From the morbidity index.
2
Cardiovascular included: Q-wave and non-Q-wave myocardial infarctions, congestive heart failure, arrhythmias requiring new medication or treatment,
cardiac ischemia requiring intervention, inotropic support, medically intractable hypertension.
3
Pulmonary included: reintubation or ventilation >24 hours, pneumonia requiring antibiotics, supplemental oxygen at discharge.
4
Renal included: dialysis in patients with normal preoperative renal function, creatinine rise >30% from baseline on two or more follow-up tests.
5
Bowel included: bowel obstruction, bowel ischemia, aorto-enteric fistula, paralytic ileus >4 days.
6
Wound included: infection requiring antibiotic treatment, hernia, lymph fistula, dehiscence, necrosis requiring debridement.
7
Neurologic included: stroke, TIA, spinal cord ischemia/paralysis.
8
Vascular included: limb thrombosis, distal embolization resulting in tissue loss or requiring intervention, transfusion post-procedure (resulting from
pseudoaneurysm, vascular injury, aneurysm leak or other procedure-related causes), pseudoaneurysm, vascular injury (such as inadvertent occlusion,
dissection or other procedure related causes), aneurysm leak or rupture, increase in aneurysm size by more than 0.5 cm relative to the smallest of any prior
measurement.
9
Investigators reported one additional high risk patient to have occlusion of an accessory renal artery and one additional high risk patient to have chronic
renal insufficiency as “other” adverse events.
10
Investigators reported one additional roll-in patient to have renal insufficiency and one additional surgical patient to have renal insufficiency as “other”
adverse events.
11
Investigators reported one additional roll-in patient to have experienced intraoperative aortic plaque rupture resulting in renal artery occlusion as an
“other” adverse event.
Table 5.1.1 Death and Rupture from Clinical Study
Death and Rupture
Zenith Standard Risk
1
Surgical Standard Risk
P
value
Zenith High Risk
Zenith Roll-in
All death
(0-30 days)
2
0.5%
(1/199)
2.5%
(2/80)
.20
2.0%
(2/100)
1.9%
(1/52)
(31-365 days)
3
3.0%
(6/198)
1.3%
(1/78)
.68
7.1%
(7/98)
9.8%
(5/51)
AAA-related
0.0%
(0/198)
1.3%
(1/78)
.29
3.1%
(3/98)
0.0%
(0/51)
Non-AAA-related
3.0%
(6/198)
0.0%
(0/78)
.19
4.1%
(4/98)
9.8%
(5/51)
(0-365 days)
2,3,4
3.5%
(7/199)
3.8%
(3/80)
>.99
9.0%
(9/100)
11.5%
(6/52)
AAA-related
0.5%
(1/199)
3.8%
(3/80)
.07
5.0%
(5/100)
1.9%
(1/52)
Non-AAA-related
3.0%
(6/199)
0.0%
(0/80)
.19
4.0%
(4/100)
9.6%
(5/52)
Rupture
0.0%
(0/199)
n/a
n/a
0.0%
(0/100)
0.0%
(0/52)
(0-30 days)
(31-365 days)
0.0%
(0/198)
n/a
n/a
1.0%
(1/98)
0.0%
(0/51)
(0-365 days)
0.0%
(0/199)
n/a
n/a
1.0%
(1/100)
0.0%
(0/52)
1
Denominator of 199 because one standard risk patient did not receive a device.
2
All deaths (0-30 days) were considered AAA and procedure related.
3
Of the deaths (31-365 days), four were considered AAA related: 1 surgical (septic shock from ischemic colitis) and 3 high risk (pancreatitis with renal failure
and sepsis, hemorrhage from upper abdominal aneurysm [not treated AAA] and multiple system failure).
4
Of the deaths (0-365 days), ten were considered AAA related: 1 standard risk (cardiac failure), 3 surgical (massive hemorrhage, mesenteric ischemia and septic
shock from ischemic colitis), 5 high risk (respiratory failure, cardiac failure with pulmonary embolism, pancreatitis with renal failure and sepsis, hemorrhage
from upper abdominal aneurysm [not treated AAA] and multiple system failure) and 1 roll-in (suspected cardiac failure).
Содержание Zenith Flex
Страница 9: ......
Страница 92: ...92 42 8 Captor Flexor 9 10 14 2 4 1 2 3 43 Spiral Z 30 mm 4 1 5 5 18 44 6 7 45 8 9...
Страница 219: ......